Therefore, inhibitors that target these Ras effector pathways could show selectivity for KRAS mutant pancreatic cancer cells.[26] In another study, the MEK and ERK inhibitors, however, did not exhibit the same level of selectivity in KRAS mutant cells in large‐scale drug sensitivity experiments.[27]. This evidence concerns the gene KRAS and familial pancreatic carcinoma.